Nalidixic acid tablets

This product is a first-generation quinolone antibacterial drug. It has antibacterial activity against some strains of Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella, Enterobacter and Haemophilus influenzae, and also has antibacterial activity against Neisseria gonorrhoeae, but has no antibacterial activity against Gram-positive cocci such as Pseudomonas, Acinetobacter and Staphylococcus. This product is a bactericide, and changes in urine pH have no effect on its action.

The chemical name is: 7-methyl-1-ethyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid.

This product is light yellow tablet.

This product is suitable for urinary tract infections caused by sensitive Gram-negative bacilli, such as Escherichia coli, Klebsiella, Proteus, Enterobacter, etc. Since Escherichia coli is currently resistant to it, it is advisable to select this drug based on drug sensitivity results.

The adult dose is 0.5 to 1 g each time, 3 times a day, for 1 to 2 weeks.

1. Gastrointestinal reactions: nausea, vomiting, diarrhea, abdominal pain. 2. Central nervous system reactions: drowsiness, weakness, headache, dizziness and vertigo. 3. Allergic reactions: rash, itching, urticaria, angioedema, eosinophilia, joint pain with joint stiffness and swelling and other allergic reactions. Direct exposure to sunlight may cause photosensitivity reactions. 4. Others: Rare cholestasis, paresthesia, metabolic acidosis, thrombocytopenia, granulocytopenia or hemolytic anemia.

Patients who are allergic to this product or have a history of convulsions are contraindicated.

Precautions for children: The safety and effectiveness of this product in infants under 3 months old have not been determined. Toxicity studies have shown that this product and related drugs can cause damage to the weight-bearing joint cartilage and other joint lesions in most immature animals tested. Therefore, this product should not be used in adolescents and children under 18 years old. Precautions for pregnancy and lactation: When the dose of this product reaches 6 times the human dose, it has a teratogenic effect on rats. This product can prolong the pregnancy period when it is 4 times the clinical dose. However, no appropriate and well-controlled studies have been conducted on pregnant women. Because this product, like other quinolones, can cause damage to the joint cartilage of immature animals, it is not suitable for pregnant women. This product can be secreted through breast milk, and because this type of drug has the potential for serious adverse effects on newborns and infants, nursing mothers should avoid using this product or stop breastfeeding when using it. Precautions for the elderly: Elderly patients often have impaired renal function. Because this product is mainly excreted through the kidneys, it needs to be used in a reduced dose.

1. When this product is used in combination with theophylline, it may increase the latter's blood concentration and cause adverse reactions of theophylline. Therefore, the blood concentration of theophylline should be monitored and the dosage should be adjusted when used in combination. 2. This product interferes with the metabolism of caffeine, which may lead to reduced caffeine clearance and prolonged plasma t1/2. 3. When this product is used in combination with the anticoagulant warfarin, it can enhance the latter's anticoagulant effect. When used in combination, the patient's prothrombin time should be closely monitored. 4. This product should not be used in combination with nitrofurantoin, as the two antagonize each other. 5. Multivitamins, or other iron- and zinc-containing preparations and antacids containing aluminum or magnesium can reduce the oral absorption of this product, resulting in a decrease in urine concentration. They should not be taken at the same time. If it cannot be avoided, the interval between taking this product and taking it should be at least 2 hours. 6. When used in combination with cyclosporine, its blood concentration can be increased. The blood concentration of cyclosporine must be monitored and the dosage adjusted. 7. When used in combination with melphalan, gastrointestinal toxicity will increase.

Keep sealed.

0.25 g

24 months